CNO Financial Group, Inc. (CNO) is scheduled to release fourth-quarter 2023 results on Feb 6, 2024, after the closing bell.Q4 EstimatesThe Zacks Consensus Estimate for CNO Financial’s fourth-quarter earnings per share is pegged at 85 cents, which indicates a 51.8% surge from the prior-year quarter’s reported figure.The consensus mark for revenues is $934 million, suggesting a 4.1% fall from the year-ago quarter’s reported number.Earnings Surprise HistoryCNO Financial’s bottom line beat estimates in one of t ...

Wall Street expects a year-over-year increase in earnings on lower revenues when CNO Financial (CNO) reports results for the quarter ended December 2023. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on February 6 ...

CNO Financial Group, Inc. (CNO) is poised for continued momentum, driven by the upward trajectory of new annualized premiums for health and life products, coupled with a steady increase in net investment income. Improvements in Life margin and Long-term care margin are additional factors expected to bolster the company's overall results.CNO Financial — with a market cap of $3.1 billion — is a top-tier holding company for a group of insurance companies operating in the United States. It administers supplemen ...

Investors might want to bet on CNO Financial (CNO) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Since a chang ...

Financial Data and Key Metrics Changes - Operating earnings per share increased to $0.88, up 31% year-over-year, and up 10% excluding significant items [7][52] - Total new annualized premium was up 13%, with strong sales growth across nearly all product categories [67] - Book value per diluted share, excluding AOCI, was $33.75, up 6% [68] Business Line Data and Key Metrics Changes - Worksite life and health insurance sales were up a record 36%, exceeding pre-pandemic sales levels by 14% [1] - Life and health NAP increased by 9%, with life production up 8% and health NAP up 11% [25][26] - Long-term care NAP surged by 48% following the launch of a new product [26] Market Data and Key Metrics Changes - Client assets in brokerage and advisory rose 18% year-over-year to $2.9 billion, with total accounts up 7% [34] - Producing agent counts increased by 24%, with agent productivity up 5% [38] - The average yield on allocated investments increased to 4.69%, up 12 basis points year-over-year [15] Company Strategy and Development Direction - The company is focused on three strategic growth priorities: integrating worksite capabilities under the Optavise brand, expanding distribution through new broker relationships, and accelerating agent recruiting [4] - The establishment of a Bermuda affiliate aims to enhance capital management and support new business opportunities [6][68] - The company is committed to serving middle-income America and enhancing customer value while driving profitable growth [42] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in ending the year strong, particularly during the critical Medicare annual enrollment period [24] - The company anticipates continued strong performance in the fourth quarter, supported by strategic investments and product enhancements [69] - Management noted that the economic environment may open more career opportunities in insurance sales, contributing to recruitment success [60][94] Other Important Information - The company completed $40 million in share repurchases during the quarter and maintained capital and liquidity above target levels [10][54] - The new accident insurance product introduced in June generated over $4 million in sales [3] Q&A Session Summary Question: How does the company plan to deploy excess capital following the Bermuda reinsurance treaty? - The company indicated that the Bermuda treaty increases excess capital at the Holdco, enhancing share repurchase capacity, but the overall deployment strategy remains unchanged [57] Question: What trends are observed in health claims experience for the fourth quarter? - Management noted that health claims moderated as expected and trends from Q3 are anticipated to continue into Q4 [92] Question: How is the company addressing agent recruitment and geographic expansion? - The company has implemented numerous support and training programs to attract talent, and is expanding its worksite business into new geographies [60][76] Question: What is the outlook for annuity collected premiums moving into 2024? - Management expects annuity business to remain healthy and attractive to middle-income consumers, despite fluctuations in interest and market conditions [85][86] Question: How does the company view the impact of new health medications on its business? - Management believes that anything improving consumer health is beneficial, as it leads to fewer claims and longer life insurance premium payments [98]

In addition to the inherent difficulty of predicting litigation outcomes, particularly those that will be decided by a jury, some matters purport to seek substantial or an unspecified amount of damages for unsubstantiated conduct spanning several years based on complex legal theories and damages models. The alleged damages typically are indeterminate or not factually supported in the complaint, and, in any event, the Company's experience indicates that monetary demands for damages often bear little relation ...

NII allocated to products benefiting from multiple quarters of +6% NMRs and growing asset base 3Q23 $40 million of share repurchases Operating ROE1 , as adjusted, of 8.5% 8 $44.5 $46.5 $47.6 $47.2 Med supp – runoff of legacy block LTC – favorable claims experience in 3Q 2023 Rising earnings power with stable credit trend Capital and liquidity remain above target levels (dollars in millions) Target leverage of 25 - 28% Debt covenant ceiling of 35% 2021 | --- | --- | |----------------------------------------- ...

Derivative Counterparty Risk REINSURANCE Table of Contents CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES Notes to Consolidated Financial Statements (unaudited) ___________________ | --- | --- | --- | |--------------------------------------------------------------|----------------------------|------------------| | | Six months June \n2023 | ended 30, \n2022 | | U.S. statutory corporate rate | 21.0 % | 21.0 % | | Non-taxable income and nondeductible benefits, net | (.5) | (.4) | | State taxes | 2.8 | 2.2 | | Eff ...

CNO Financial Group, Inc. (NYSE:CNO) Q2 2023 Earnings Conference Call August 2, 2023 11:00 AM ET Company Participants Adam Auvil - Investor Relations Gary Bhojwani - Chief Executive Officer Paul McDonough - Chief Financial Officer Eric Johnson - President and Chief Investment Officer Karen DeToro - Chief Actuary Conference Call Participants Erik Bass - Autonomous John Barnidge - Piper Sandler Brian Kruger - Stifel Wilma Burdis - Raymond James Scott Heleniak - RBC Capital Suneet Kamath - Jefferies Tom Gallag ...

1 Measured as 100% of new life and health annualized premiums, except for single premium whole life deposits, which are measured at 10% of annualized premium. 2 Client assets include cash and securities in brokerage, broker/dealer customer account assets custodied directly at fund companies and insurance carriers, and assets under management in advisory accounts. 3 Represents fee revenue from the sales of third-party insurance products; services provided by WBD; fee revenue earned by Optavise (formerly know ...